February 7, 2019Open Access
View Full PaperFull Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
Structured PICO
Does andexanet alfa improve hemostatic efficacy in patients with acute major bleeding associated with the use of a factor Xa inhibitor?
P
Population
Patients with acute major bleeding associated with the use of a factor Xa inhibitor
I
Intervention
Andexanet alfa
O
Outcome
Anti-factor Xa activity and hemostatic efficacy at 12 hours (adjudicated according to prespecified criteria)hard clinical
Andexanet alfa effectively reduces anti-factor Xa activity and provides excellent or good hemostatic efficacy in patients with acute major bleeding on factor Xa inhibitors.
Abstract
In patients with acute major bleeding associated with the use of a factor Xa inhibitor, treatment with andexanet markedly reduced anti-factor Xa activity, and 82% of patients had excellent or good hemostatic efficacy at 12 hours, as adjudicated according to prespecified criteria. (Funded by Portola Pharmaceuticals; ANNEXA-4 ClinicalTrials.gov number, NCT02329327.).